Form 4: Tango Therapeutics R&D President Exercises, Sells Shares

Tango Therapeutics' President of R&D, Adam Crystal, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

Summary

• Adam Crystal, President, R&D of Tango Therapeutics, Inc. (TNGX), engaged in transactions involving the company's common stock and stock options.
• On March 25, 2026, 12,000 shares of common stock were acquired through the exercise of stock options at a price of $5.20 per share.
• Concurrently, 12,000 shares of common stock were sold at a weighted-average price of $20.11 per share, with individual sales ranging from $20.00 to $20.27.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
• Following these reported transactions, Adam Crystal directly beneficially owns 112,622 shares of common stock and 460,500 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a 10b5-1 plan, reflecting an executive taking some profits from vested options. The significant profit margin on the options exercise is a positive indicator of past stock performance.

Positives

• The insider realized a significant profit by exercising options at $5.20 per share and selling the shares at a weighted-average price of $20.11 per share, indicating substantial appreciation in the company's stock value.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests pre-planned activity and reduces concerns about opportunistic trading based on immediate non-public information.

Negatives

• The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some investors as a signal of the executive taking profits, potentially indicating a belief that the stock's near-term upside may be limited, although it is a common liquidity event.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive stock option exercises and subsequent sales are common events in the biotechnology sector, often representing a liquidity event for long-tenured executives. The use of a 10b5-1 plan indicates a pre-planned transaction, which is a standard practice for managing insider trading compliance.

Comparison to Industry Standards

• Executive compensation structures in the biotech industry frequently include significant equity components, such as stock options, to align management incentives with shareholder value creation.
• The exercise and sale of options at a substantial profit margin (over 3x the exercise price) is typical for successful executives in companies that have seen stock appreciation, similar to recent executive transactions observed at peers like Moderna or BioNTech during periods of growth.

Stakeholder Impact

• Shareholders: May view the sale as an executive taking profits, but the 10b5-1 plan mitigates concerns about opportunistic selling. The profit realized indicates past stock appreciation.
• Employees: No direct impact on employees is mentioned in this filing.

Key Dates

Recommendation

The filing details a routine insider transaction under a 10b5-1 plan, where an executive exercised options and sold shares for liquidity. While the sale itself isn't a strong buy signal, the pre-planned nature and the significant profit realized from the option exercise suggest past positive performance. This filing alone does not provide sufficient new information to warrant a change from a 'hold' position, as it reflects standard executive compensation management rather than a new strategic or operational development.

Keywords

Tango Therapeutics, TNGX, Form 4, Insider Trading, Stock Options, Share Sale, Adam Crystal, 10b5-1 Plan, Biotechnology, Executive Compensation